Dushyant Verma

710 total citations
14 papers, 486 citations indexed

About

Dushyant Verma is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Dushyant Verma has authored 14 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Hematology and 5 papers in Rheumatology. Recurrent topics in Dushyant Verma's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Eosinophilic Disorders and Syndromes (5 papers). Dushyant Verma is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Eosinophilic Disorders and Syndromes (5 papers). Dushyant Verma collaborates with scholars based in United States, South Africa and Vietnam. Dushyant Verma's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Gautam Borthakur, Farhad Ravandi, Srđan Verstovšek, Susan O’Brien, Dan Jones, Mary Beth Rios, Rajyalakshmi Luthra and Elias Jabbour and has published in prestigious journals such as Blood, Cancer and American Journal of Hematology.

In The Last Decade

Dushyant Verma

14 papers receiving 465 citations

Peers

Dushyant Verma

HEMAT

GENET

RHEUM

PHEOH

J. Janssen Netherlands

Ravin J. Garg United States

Mona Lisa Alattar United States

Nadja Jaekel Germany

А К Голенков Russia

Emilia Scalzulli Italy

M. T. Daniel France

DK Hossfeld Germany

Greg Malnassy United States

Arjan van de Loosdrecht Netherlands

J. Janssen Netherlands

Dushyant Verma

285 ×0.7

HEMAT

222 ×0.8

GENET

111 ×1.0

RHEUM

75 ×0.7

49 ×0.7

PHEOH

Citations per year, relative to Dushyant Verma Dushyant Verma (= 1×) peers J. Janssen

Countries citing papers authored by Dushyant Verma

Since Specialization

Citations

This map shows the geographic impact of Dushyant Verma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dushyant Verma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dushyant Verma more than expected).

Fields of papers citing papers by Dushyant Verma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dushyant Verma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dushyant Verma. The network helps show where Dushyant Verma may publish in the future.

Co-authorship network of co-authors of Dushyant Verma

This figure shows the co-authorship network connecting the top 25 collaborators of Dushyant Verma. A scholar is included among the top collaborators of Dushyant Verma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dushyant Verma. Dushyant Verma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Falchi, Lorenzo, Hagop M. Kantarjian, Xuemei Wang, et al.. (2013). Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology. 88(12). 1024–1029. 40 indexed citations

Verma, Dushyant, Hagop M. Kantarjian, Sara S. Strom, et al.. (2011). Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 118(16). 4353–4358. 71 indexed citations

Verma, Dushyant, Hagop M. Kantarjian, Jianqin Shan, et al.. (2010). Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 116(11). 2673–2681. 39 indexed citations

Verma, Dushyant, Hagop M. Kantarjian, Stefan Faderl, et al.. (2010). Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leukemia & lymphoma. 51(5). 778–782. 44 indexed citations

Santos, Fabio P S, Dan Jones, Wei Qiao, et al.. (2010). Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 117(10). 2145–2155. 87 indexed citations

Santos, Fábio Pires de Souza, Yesid Alvarado, Hagop M. Kantarjian, et al.. (2010). Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 117(5). 982–991. 10 indexed citations

Balakrishnan, Kumudha, Dushyant Verma, Susan O’Brien, et al.. (2010). Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 116(6). 886–892. 34 indexed citations

Verma, Dushyant, Hagop M. Kantarjian, Dan Jones, et al.. (2009). Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 114(11). 2232–2235. 115 indexed citations

Verma, Dushyant, Hagop M. Kantarjian, Jenny Shan, et al.. (2009). Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.. Blood. 114(22). 505–505. 8 indexed citations

10.

Verma, Dushyant, Susan O’Brien, Deborah A. Thomas, et al.. (2008). Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 115(1). 101–106. 11 indexed citations

11.

Verma, Dushyant, Hagop M. Kantarjian, Nitin Jain, & Jörge E. Cortes. (2008). Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leukemia & lymphoma. 49(7). 1399–1402. 23 indexed citations

12.

Borthakur, Gautam, Miloslav Beran, Jun Liu, et al.. (2008). Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.. Blood. 112(11). 3235–3235. 1 indexed citations

13.

Vu, Khanh Dang, Sai‐Ching J. Yeung, Deborah A. Thomas, et al.. (2008). Effect of Tight Control of Blood Glucose during Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia.. Blood. 112(11). 904–904. 2 indexed citations

14.

Verma, Dushyant, Hagop M. Kantarjian, Zeev Estrov, et al.. (2007). Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.. Blood. 110(11). 2949–2949. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact